EXONDYS 51 (ETEPLIRSEN) Trademark

Trademark Overview

On Friday, July 30, 2021, a trademark application was filed for EXONDYS 51 (ETEPLIRSEN) with the United States Patent and Trademark Office. The USPTO has given the EXONDYS 51 (ETEPLIRSEN) trademark a serial number of 90857980. The federal status of this trademark filing is REGISTERED as of Tuesday, April 18, 2023. This trademark is owned by Sarepta Therapeutics, Inc.. The EXONDYS 51 (ETEPLIRSEN) trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations featuring antisense oligonucleotides for the treatment of neuromuscular diseases and disorders
exondys 51 (eteplirsen)

General Information

Serial Number90857980
Word MarkEXONDYS 51 (ETEPLIRSEN)
Filing DateFriday, July 30, 2021
Status700 - REGISTERED
Status DateTuesday, April 18, 2023
Registration Number7032061
Registration DateTuesday, April 18, 2023
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, March 22, 2022

Trademark Statements

Description of MarkThe mark consists of a hexagon, encircled by a sash, followed by the text and numeral "EXONDYS 51" above the text "(eteplirsen)".
Goods and ServicesPharmaceutical preparations featuring antisense oligonucleotides for the treatment of neuromuscular diseases and disorders
Pseudo MarkEXONDYS FIFTY ONE (ETEPLIRSEN); EXONDYS FIVE ONE (ETEPLIRSEN)
Disclaimer with Predetermined Text"51" AND "ETEPLIRSEN"

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, September 27, 2021
Primary Code005
First Use Anywhere DateWednesday, February 19, 2020
First Use In Commerce DateWednesday, February 19, 2020

Trademark Owner History

Party NameSarepta Therapeutics, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142
Party NameSarepta Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142
Party NameSarepta Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142

Trademark Events

Event DateEvent Description
Tuesday, April 18, 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, April 18, 2023REGISTERED-PRINCIPAL REGISTER
Tuesday, March 14, 2023NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Sunday, March 12, 2023ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, February 21, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, February 21, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 21, 2023ASSIGNED TO LIE
Thursday, December 15, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, December 12, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, December 12, 2022NON-FINAL ACTION E-MAILED
Monday, December 12, 2022SU - NON-FINAL ACTION - WRITTEN
Thursday, November 24, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 23, 2022STATEMENT OF USE PROCESSING COMPLETE
Saturday, November 12, 2022USE AMENDMENT FILED
Wednesday, November 23, 2022SOU EXTENSION 1 GRANTED
Saturday, November 12, 2022SOU EXTENSION 1 FILED
Wednesday, November 23, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Saturday, November 12, 2022TEAS EXTENSION RECEIVED
Saturday, November 12, 2022TEAS STATEMENT OF USE RECEIVED
Tuesday, May 17, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 22, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 22, 2022PUBLISHED FOR OPPOSITION
Wednesday, March 2, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, February 14, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, February 11, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, February 11, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, February 11, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, February 9, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, February 9, 2022NON-FINAL ACTION E-MAILED
Wednesday, February 9, 2022NON-FINAL ACTION WRITTEN
Monday, February 7, 2022EXAMINER'S AMENDMENT ENTERED
Monday, February 7, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, February 7, 2022EXAMINERS AMENDMENT E-MAILED
Monday, February 7, 2022EXAMINERS AMENDMENT -WRITTEN
Wednesday, February 2, 2022ASSIGNED TO EXAMINER
Tuesday, September 28, 2021NOTICE OF DESIGN SEARCH CODE E-MAILED
Monday, September 27, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, August 3, 2021NEW APPLICATION ENTERED

Related Keywords

eteplirsen exondys neuromuscular diseases disorders treatment oligonucleotides preparations featuring antisense pharmaceutical